Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Sep 23, 2022 12:39pm
137 Views
Post# 34982224

Special Meeting. Oct. 31st

Special Meeting. Oct. 31stAny speculation as to the reason for this special meeting ?  Interesting that whatever the reason that it could not be done at an AGM.
Also interesting that the date is after the end of the 1 year Arbitration (assuming it ends on Oct. 18th).

Is it a shareholder information meeting: 
 * Announcing the Arbitrators findings.
* Possibly some deal has been struck with Shiseido
* The company is being sold
* Private Placement disclosure (who's buying and what impact that has on the ownership of shares)
* Dermal Injector is being submitted to the FDA for Approval
* New partnerships in Japan
* Yofoto launches RCS-01 and RCT-01 Trials

Wouldn't it be nice to get all of the above information but sadly it most likely will be none of the above.



<< Previous
Bullboard Posts
Next >>